A trifluoromethyl analogue of celecoxib exerts beneficial effects in neuroinflammation

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Di Penta, Alessandra ^a,b   Chiba, Asako ^c,d   Alloza, Iraide ^a,b,e   Wyssenbach, Ane ^a   Yamamura, Takashi ^c   Villoslada, Pablo ^f   Miyake, Sachiko ^c,d   Vandenbroeck, Koen ^a,b,e  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b ACHUCARRO BASQUE CENTER FOR NEUROSCIENCE   (Spain)

^c NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e BASQUE FOUNDATION FOR SCIENCE   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; RANTES; TRIFLUOROMETHYL DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; LIPOPOLYSACCHARIDE; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; AXONAL INJURY; CELL STRESS; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; MYELOID DENDRITIC CELL; NERVE CELL LESION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN SYNTHESIS INHIBITION; T LYMPHOCYTE; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INFLAMMATION; METABOLISM; NERVE FIBER; PATHOLOGY;

ANIMALS; ASTROCYTES; AXONS; CELLS, CULTURED; CYCLOOXYGENASE 2 INHIBITORS; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INFLAMMATION; LIPOPOLYSACCHARIDES; MICE; MULTIPLE SCLEROSIS; PYRAZOLES; SULFONAMIDES;

EID: 84892615981     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083119     Document Type: Article

References (73)

1. Shi S, Klotz U (2008) Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 64: 233-252. doi:10.1007/s00228-007-0400-7. PubMed: 17999057.
2. DeWitt DL (1999) Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol 55: 625-631. PubMed: 10101019.
3. Grösch S, Tegeder I, Niederberger E, Bräutigam L, Geisslinger G (2001) COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15: 2742-2744. PubMed: 11606477.
4. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP et al. (2004) 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 64: 1444-1451. doi:10.1158/0008-5472.CAN-03-2396. PubMed: 14973075.
5. Alloza I, Baxter A, Chen Q, Matthiesen R, Vandenbroeck K (2006) Celecoxib inhibits interleukin-12 alphabeta and beta2 folding and secretion by a novel COX2-independent mechanism involving chaperones of the endoplasmic reticulum. Mol Pharmacol 69: 1579-1587. doi:10.1124/mol.105.020669. PubMed: 16467190.
6. McLaughlin M, Alloza I, Quoc HP, Scott CJ, Hirabayashi Y et al. (2010) Inhibition of secretion of interleukin (IL)-12/23 family cytokines by 4-trifluoromethyl-celecoxib is coupled to degradation via the endoplasmic reticulum stress protein HERP. J Biol Chem 285: 6960-6969. doi:10.1074/jbc.M109. 056614. PubMed: 20054003.
7. Vandenbroeck K, Alloza I, Brehmer D, Billiau A, Proost P et al. (2002) The conserved helix C region in the superfamily of interferon-gamma/interleukin- 10-related cytokines corresponds to a high-affinity binding site for the HSP70 chaperone DnaK. J Biol Chem277: 25668-25676. doi:10.1074/jbc.M202984200. PubMed: 11970958.
8. Vandenbroeck K, Martens E, Alloza I (2006) Multi-chaperone complexes regulate the folding of interferon-gamma in the endoplasmic reticulum. Cytokine 33: 264-273. doi:10.1016/j.cyto.2006.02.004. PubMed: 16574426.
9. McLaughlin M, Vandenbroeck K (2011) The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery? Br J Pharmacol 162: 328-345. doi:10.1111/j.1476-5381.2010.01064.x. PubMed: 20942857.
10. Johnson AJ, Hsu AL, Lin HP, Song X, Chen CS (2002) The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J 366: 831-837. PubMed: 12076251.
11. Kardosh A, Golden EB, Pyrko P, Uddin J, Hofman FM et al. (2008) Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Res, 68: 843-851. doi:10.1158/0008- 5472.CAN-07-5555. PubMed: 18245486.
12. Okada T, Yoshida H, Akazawa R, Negishi M, Mori K (2002) Distinct roles of activating transcription factor 6 (ATF6) and double-stranded RNA-activated protein kinase-like endoplasmic reticulum kinase (PERK) in transcription during the mammalian unfolded protein response. Biochem J 366: 585-594. doi:10.1042/BJ20020391. PubMed: 12014989.
13. Oyadomari S, Mori M (2004) Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 11: 381-389. doi:10.1038/sj.cdd.4401373. PubMed: 14685163.
14. Ni J, Shu YY, Zhu YN, Fu YF, Tang W et al. (2007) COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression. J Neuroimmunol 186: 94-103. doi:10.1016/j.jneuroim. 2007.03.012. PubMed: 17442406.
15. Reder AT, Thapar M, Sapugay AM, Jensen MA (1994) Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis. J Neuroimmunol 54: 117-127. doi:10.1016/0165-5728(94)90238-0. PubMed: 7523442.
16. Miyamoto K, Miyake S, Mizuno M, Oka N, Kusunoki S et al. (2006) Selective COX-2-inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway. Brain 129: 1984-1992. doi:10.1093/brain/ awl170. PubMed: 16835249.
17. Chiba A, Mizuno M, Tomi C, Tajima R, Alloza I, et al. (2012) A 4-trifluoromethyl analogue of celecoxib inhibits arthritis by suppressing innate immune cell activation. Arthritis Res Ther 14: R9.
18. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B et al. (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342: c7086. doi:10.1136/bmj.c7086. PubMed: 21224324.
19. Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT et al. (2009) Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2: 155-163. doi:10.1161/CIRCOUTCOMES.108.805689. PubMed: 20031832.
20. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J et al. (2008) Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117: 2104-2113. doi:10.1161/ CIRCULATIONAHA.108.764530. PubMed: 18378608.
21. Feng GS, Ma JL, Wong BC, Zhang L, Liu WD, et al. (2008) Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World J Gastroenterol 14: 4535-4539.
22. Haag MDM, Bos MJ, Hofman A, Koudstaal PJ, Breteler MMB et al. (2008) Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med 168: 1219-1224. doi:10.1001/archinte.168.11.1219. PubMed: 18541831.
23. Grosser T, Fries S, FitzGerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 116: 4-15. PubMed: 16395396.
24. Pidgeon GP, Tamosiuniene R, Chen G, Leonard I, Belton O et al. (2004) Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2. Circulation 110: 2701-2707. doi:10.1161/01.CIR. 0000145613.01188.0B. PubMed: 15492320.
25. Buerkle MA, Lehrer S, Sohn H-Y, Conzen P, Pohl U et al. (2004) Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hámster arterioles in vivo. Circulation 110: 2053-2059. doi:10.1161/01.CIR.0000143234. 51796.A9. PubMed: 15451781.
26. Stoppini L, Buchs PA, Muller D (1991) A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 37: 173-182. doi:10.1016/0165- 0270(91)90128-M. PubMed: 1715499.
27. Dusart I, Airaksinen MS, Sotelo C (1997) Purkinje cell survival and axonal regeneration are age dependent: an in vitro study. J Neurosci 17: 3710-3726. PubMed: 9133392.
28. Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F (1990) Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol 27: 229-237. doi:10.1016/0165-5728(90)90073-V. PubMed: 2110186.
29. McCarthy KD, de Vellis J (1980) Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85: 890-902. doi:10.1083/jcb.85.3.890. PubMed: 6248568.
30. Fan LW, Tien LT, Mitchell HJ, Rhodes PG, Cai Z (2008) Alpha-phenyl-n-tert-butyl-nitrone ameliorates hippocampal injury and improves learning and memory in juvenile rats following neonatal exposure to lipopolysaccharide. Eur J Neurosci 27: 1475-1484.
31. Kim JY, Shen S, Dietz K, He Y, Howell O et al. (2010) HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat Neurosci 13: 180-189. doi:10.1038/nn.2471. PubMed: 20037577.
32. Di Penta A, Moreno B, Reix S, Fernandez-Diez B, Villanueva M et al. (2013) Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation. PLOS-ONE 8: e54722. doi:10.1371/journal.pone.0054722.
33. Sherwin C, Fern R (2005) Acute lipopolysaccharide-mediated injury in neonatal white matter glia: role of TNF-alpha, IL-1beta, and calcium. J Immunol 175: 155-161. PubMed: 15972642.
34. Coleman M (2005) Axon degeneration mechanisms: commonality amid diversity. Nat Rev Neurosci 6: 889-898. doi:10.1038/nrn1788. PubMed: 16224497.
35. Wheeler MC, Rizzi M, Sasik R, Almanza G, Hardiman G, et al. (2008) KDEL-retained antigen in B lymphocytes induces a proinflammatory response: a possible role for endoplasmic reticulum stress in adaptive T cell immunity. J Immunol 181: 256-264.
36. Ron D, Habener JF (1992) CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev 6: 439-453. doi:10.1101/gad.6.3.439. PubMed: 1547942.
37. Chung IY, Benveniste EN (1990) Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta. J Immunol 144: 2999-3007.
38. Johnson AJ, Hsu AL, Lin HP, Song X, Chen CS (2002) The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J 366: 831-837. PubMed: 12076251.
39. Cornell-Bell AH, Finkbeiner SM, Cooper MS, Smith SJ (1990) Glutamate induces calcium waves in cultured astrocytes: long-range glial signaling. Science 247: 470-473.
40. Charles AC, Merrill JE, Dirksen ER, Sanderson MJ (1991) Intercellular signaling in glial cells: calcium waves and oscillations in response to mechanical stimulation and glutamate. Neuron 6: 983-992. doi:10.1016/0896- 6273(91)90238-U. PubMed: 1675864.
41. Parpura V, Basarsky TA, Liu F, Jeftinija K, Jeftinija S et al. (1994) Glutamate-mediated astrocyte-neuron signalling. Nature 369: 744-747. doi:10.1038/369744a0. PubMed: 7911978.
42. Pasti L, Volterra A, Pozzan T, Carmignoto G (1997) Intracellular calcium oscillations in astrocytes: a highly plastic, bidirectional form of communication between neurons and astrocytes in situ. J Neurosci 17: 7817-7830. PubMed: 9315902.
43. Newman EA, Zahs KR (1997) Calcium waves in retinal glial cells. Science 275: 844-857. doi:10.1126/science.275.5301.844. PubMed: 9012354.
44. Bezzi P, Carmignoto G, Pasti L, Vesce S, Rossi D et al. (1998) Prostaglandins stimulate calciumdependent glutamate release in astrocytes. Nature 391: 281-285. doi:10.1038/34651. PubMed: 9440691.
45. Innocenti B, Parpura V, Haydon PG (2000) Imaging extracellular waves of glutamate during calcium signaling in cultured astrocytes. J Neurosci 20: 1800-1808. PubMed: 10684881.
46. Bezzi P, Domercq M, Brambilla L, Galli R, Schols D et al. (2001) CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci 4: 702-710. doi:10.1038/89490. PubMed: 11426226.
47. Hoffmann A, Kann O, Ohlemeyer C, Hanisch UK, Kettenmann H (2003) Elevation of basal intracellular calcium as a central element in the activation of brain macrophages (microglia): suppression of receptorevoked calcium signaling and control of release function. J Neurosci 23: 4410-4419
48. Meurer R, Van Riper G, Feeney W, Cunningham P, Hora D Jr et al. (1993) Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not human monocyte chemoattractant protein 1, human macrophage inflammatory protein 1 alpha, or human interleukin 8. J Exp Med 178: 1913-1921. doi:10.1084/jem.178.6.1913. PubMed: 7504053.
49. Schall TJ, Bacon K, Toy KJ, Goeddel DV (1990) Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 347: 669-671. doi:10.1038/347669a0. PubMed: 1699135.
50. Conti P, Reale M, Barbacane RC, Letourneau R, Theoharides TC (1998) Intramuscular injection of hrRANTES causes mast cell recruitment and increased transcription of histidine decarboxylase in mice: lack of effects in genetically mast cell-deficient W/WV mice. FASEB J 12: 1693-1700. PubMed: 9837859.
51. Das AM, Ajuebor MN, Flower RJ, Perretti M, McColl SR (1999) Contrasting roles for RANTES and macrophage inflammatory protein-1 alpha (MIP-1 alpha) in a murine model of allergic peritonitis. Clin Exp Immunol 117: 223-229. doi:10.1046/j.1365-2249.1999.00978.x. PubMed: 10444251.
52. Weber C, Weber KS, Klier C, Gu S, Wank R et al. (2001) Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T(H)1-like/CD45RO(+) T cells. Blood 97: 1144-1146. doi:10.1182/blood.V97.4.1144. PubMed: 11159551.
53. Barnes DA, Huston M, Holmes R, Benveniste EN, Yong VW et al. (1996) Induction of RANTES expression by astrocytes and astrocytoma cell lines. J Neuroimmunol 71: 207-214. doi:10.1016/S0165-5728(96)00154-3. PubMed: 8982121.
54. Selmaj K, Raine CS, Cross AH (1991) Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 30: 694-700. doi:10.1002/ana. 410300510. PubMed: 1722388.
55. Baker D, Butler D. D, Scallon BJ, O'Neill JK, Turk JL et al. (1994) Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 24: 2040-2048. doi:10.1002/eji.1830240916. PubMed: 8088324. Available online at: doi:10.1002/eji.1830240916 Available online at: PubMed: 8088324
56. Hofman FM, Hinton DR, Johnson K, Merrill JE (1989) Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med, 170: 607-612. doi:10.1084/jem.170.2.607. PubMed: 2754393.
57. Sharief MK, Hentges R (1991) Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325: 467-472. doi:10.1056/NEJM199108153250704. PubMed: 1852181.
58. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G (1995) Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci U S A 92: 11294-11298. doi:10.1073/pnas.92.24.11294. PubMed: 7479982.
59. Grell M, Wajant H, Zimmermann G, Scheurich P (1998) The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A 95: 570-575. doi:10.1073/pnas.95.2.570. PubMed: 9435233.
60. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117: 244-279. doi:10.1016/j.pharmthera.2007.10.001. PubMed: 18155297.
61. Yang L, Lindholm K, Konishi Y, Li R, Shen Y (2002) Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J Neurosci 22: 3025-3032. PubMed: 11943805.
62. Suvannavejh GC, Lee HO, Padilla J, Dal Canto MC, Barrett TA et al. (2000) Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG (35-55)-induced experimental autoimmune encephalomyelitis. Cell Immunol 205: 24-33. doi:10.1006/cimm.2000.1706. PubMed: 11078604.
63. Kassiotis G, Kollias G (2001) Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 193: 427-434. doi:10.1084/jem.193.4.427. PubMed: 11181695.
64. Caminero A, Comabella M, Montalban X (2011) Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story. J Neuroimmunol 234: 1-6. doi:10.1016/j.jneuroim.2011.03.004. PubMed: 21474190.
65. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 441: 235-238. doi:10.1038/nature04753. PubMed: 16648838.
66. Veldhoen M, Hocking RJ, Atkins CH, Locksley RM, Stockinger B (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation ofmIL-17-producin cells. Immunity 24: 179-189. doi:10.1016/j.immuni.2006.01.001. PubMed: 16473830.
67. de Vries HE, Blom-Roosemalen MC, van Oosten M, de Boer AG, van Berkel TJ et al. (1996) The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol 64: 37-43. doi:10.1016/0165-5728(95)00148-4. PubMed: 8598388.
68. Cannella B, Raine CS (1995) The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37: 424-435. doi:10.1002/ana.410370404. PubMed: 7536402.
69. Woodroofe MN, Cuzner ML (1993) Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine 5: 583-588. doi:10.1016/S1043-4666(05)80008-0. PubMed: 8186370.
70. Agnello D, Bigini P, Villa P, Mennini T, Cerami A et al. (2002) Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoinmune encephalomyelitis. Brain Res 952: 128-134. doi:10.1016/S0006-8993(02)03239-0. PubMed: 12363412.
71. Eugster HP, Frei K, Kopf M, Lassmann H, Fontana A (1998) IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol 28: 2178-2187. doi:10.1002/(SICI)1521- 4141(199807)28:07. PubMed: 9692887.
72. Brett FM, Mizisin AP, Powell HC, Campbell IL (1995) Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes. J Neuropathol Exp Neurol 54: 766-775. doi:10.1097/00005072-199511000-00003. PubMed: 7595649.
73. Castro-Borrero W, Graves D, Frohman TC, Bates Flores A, Hardeman P et al. (2012) Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord 5: 205-220. doi:10.1177/1756285612450936. PubMed: 22783370.